Scopus BioPharma Inc. (SCPS)

[FACT-MASTER]

13.Subsequent Events

Other than what is disclosed below, or elsewhere in these notes, there are no material subsequent events requiring additional disclosure.

On April 7, 2022, we entered into a sponsored research agreement (the “Kortylewski SRA”) with COH for research to be conducted by Marcin Kortylewski, Ph.D., a Co-Founder and Senior Advisor of Duet and Professor in the Department of Immuno-Oncology at COH. Pursuant to the Kortylewski SRA, Dr. Kortylewski and his lab will be evaluating novel chemical structures and formulations to increase the stability of siRNA-based molecules to enable systemic delivery. The research under the Kortylewski SRA is expected to be conducted over a two-year period at a cost of approximately $200,000 per year.

https://ih.advfn.com/stock-market/NASDAQ/scopus-biopharma-SCPS/stock-news/87842277/annual-report-10-k